Antitrust Antitrust

Mallinckrodt US bankruptcy filing pauses antitrust litigation over infantile spasm drug

By Max Fillion
  • 13 Oct 2020 17:36
  • 13 Oct 2020 17:56
Mallinckrodt Pharmaceuticals filed for US bankruptcy yesterday, putting the brakes on several ongoing suits accusing the company of monopolizing the infantile spasm drug Acthar.
In a release, Mallinckrodt said it “voluntarily initiated Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware to modify its capital structure, including

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News